Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 13/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 13/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 8/20 | 0.42 |
| ▸ | CASP7 | P55210 | 7/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311910 | 0.92 | CASP1 (0.47) | USP5CASP1TSHRCASP3CASP8 | |
| SCHEMBL12569650 | 0.92 | CASP1 (0.47) | USP5CASP1TSHRCASP3CASP8 | |
| SCHEMBL311069 | 0.88 | USP5 (0.58) | USP5CASP1TSHRCASP3CASP8 | |
| SCHEMBL12569598 | 0.87 | CASP3 (0.43) | CASP1CASP3CASP8CASP7 | |
| SCHEMBL79719 | 0.87 | CASP1 (0.41) | CASP1CASP3CASP8CASP7 | |
| SCHEMBL12569600 | 0.87 | CASP3 (0.47) | CASP1CASP3CASP8CASP7CASP9 | |
| SCHEMBL92919 | 0.87 | CASP1 (0.41) | CASP1CASP3CASP8CASP7 | |
| SCHEMBL311857 | 0.86 | USP5 (0.50) | USP5CASP1TSHRCASP3CASP8 | |
| SCHEMBL311415 | 0.85 | CASP1 (0.42) | CASP1CASP3CASP8CASP7 | |
| SCHEMBL8348714 | 0.85 | USP5 (0.44) | USP5CASP1TSHRCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288537-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-29 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093392-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-10 | — | — | US | disclosed |
| US-7960398-B2 | Potent inhibitors of TNF activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-14 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517987-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080199454-A1 | Phospholipid covalently linked to caspase inhibitor, such that the active group is released at the required site of disease such as inflammatory and degenerative diseases | MORTIMORE MICHAEL | 2008-08-21 | — | — | US | disclosed |
| US-20080199454-A1 | Phospholipid covalently linked to caspase inhibitor, such that the active group is released at the required site of disease such as inflammatory and degenerative diseases | MORTIMORE MICHAEL | 2008-08-21 | — | — | US | disclosed |
| US-7410956-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410956-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-12 | — | — | US | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| WO-2003068242-A1 | PHOSPHOLIPIDS AS CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-21 | — | — | WO | disclosed |
| EP-1244626-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001042216-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077830-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP2 | USP5 403/4885CASP1 1/4885TSHR 4750/4885 |
| US-20080199454-A1 | Phospholipid covalently linked to caspase inhibitor, such that the active group is released at the required site of disease such as inflammatory and degenerative diseases | CASP1, CASP5, CASP2 | USP5 564/4885CASP1 1/4885TSHR 4762/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | USP5 359/4885CASP1 1/4885TSHR 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.